<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E4599F86-E5D9-40AD-A427-4782E12EA8BF"><gtr:id>E4599F86-E5D9-40AD-A427-4782E12EA8BF</gtr:id><gtr:name>Swiss Federal Institute of Technology in Lausanne (EPFL)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FA143EC1-E637-4E0C-80ED-0EA8ED214038"><gtr:id>FA143EC1-E637-4E0C-80ED-0EA8ED214038</gtr:id><gtr:name>University of Leuven</gtr:name><gtr:address><gtr:line1>Oude Markt 13</gtr:line1><gtr:line2>Box 5005</gtr:line2><gtr:region>outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7479EFF8-8EF7-479B-BB26-3D844EB92D8E"><gtr:id>7479EFF8-8EF7-479B-BB26-3D844EB92D8E</gtr:id><gtr:name>University of Goettingen</gtr:name><gtr:address><gtr:line1>Windausweg 2</gtr:line1><gtr:postCode>D-37073</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7BC6FCF2-358C-45C5-A5A7-E859DD754711"><gtr:id>7BC6FCF2-358C-45C5-A5A7-E859DD754711</gtr:id><gtr:name>Lund University</gtr:name><gtr:address><gtr:line1>Box 117</gtr:line1><gtr:line2>S-221 00</gtr:line2><gtr:line4>Lund</gtr:line4><gtr:postCode>S-221 00</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C845432E-F996-4049-AC78-C51220E0C406"><gtr:id>C845432E-F996-4049-AC78-C51220E0C406</gtr:id><gtr:name>H. Lundbeck A/S</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Physiology Anatomy and Genetics</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E4599F86-E5D9-40AD-A427-4782E12EA8BF"><gtr:id>E4599F86-E5D9-40AD-A427-4782E12EA8BF</gtr:id><gtr:name>Swiss Federal Institute of Technology in Lausanne (EPFL)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FA143EC1-E637-4E0C-80ED-0EA8ED214038"><gtr:id>FA143EC1-E637-4E0C-80ED-0EA8ED214038</gtr:id><gtr:name>University of Leuven</gtr:name><gtr:address><gtr:line1>Oude Markt 13</gtr:line1><gtr:line2>Box 5005</gtr:line2><gtr:region>outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7479EFF8-8EF7-479B-BB26-3D844EB92D8E"><gtr:id>7479EFF8-8EF7-479B-BB26-3D844EB92D8E</gtr:id><gtr:name>University of Goettingen</gtr:name><gtr:address><gtr:line1>Windausweg 2</gtr:line1><gtr:postCode>D-37073</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7BC6FCF2-358C-45C5-A5A7-E859DD754711"><gtr:id>7BC6FCF2-358C-45C5-A5A7-E859DD754711</gtr:id><gtr:name>Lund University</gtr:name><gtr:address><gtr:line1>Box 117</gtr:line1><gtr:line2>S-221 00</gtr:line2><gtr:line4>Lund</gtr:line4><gtr:postCode>S-221 00</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C845432E-F996-4049-AC78-C51220E0C406"><gtr:id>C845432E-F996-4049-AC78-C51220E0C406</gtr:id><gtr:name>H. Lundbeck A/S</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/9F8F75E8-87B5-4842-975A-FEF86EB86988"><gtr:id>9F8F75E8-87B5-4842-975A-FEF86EB86988</gtr:id><gtr:firstName>Richard</gtr:firstName><gtr:surname>Wade-Martins</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FN029453%2F1"><gtr:id>0D99A533-1AF5-4DAF-8073-DA2005FDE4D3</gtr:id><gtr:title>JPND Alpha-synuclein pathology propagation in Parkinson's disease and quest for novel protective strategies</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/N029453/1</gtr:grantReference><gtr:abstractText>Misfolding and aggregation of a protein named alpha-synuclein (alpha-syn) causes protein clumps in the brain called Lewy bodies leading to damage to the brain and Parkinson's disease (PD). Accumulating evidence shows that alpha-syn protein isolated from a PD patient brain may be taken up into brain cells in a tissue culture dish or in a mouse. This suggests that the protein may spread and the pathology may spread. Many fundamental questions still need to be answered in order to advance our understanding of the origin and the molecular mechanisms of PD with a view to design innovative protective strategies. For example, 1) how do alpha-syn aggregates form; do they start in the brain, or perhaps even in the gut as some people think, and how do environmental factors, including gut bacteria, contribute to this process; 2) how does alpha-syn protein spread from cell-to-cell?; 3) how does alpha-syn shift from a normal state to a disease state? 4) how, and through which route(s), is/are misfolded/aggregated alpha-syn transported and spread from one cell to another?; 5) how do genetics contribute to the spread of pathological alpha-syn?; 6) can small molecule compounds and biological reagents, such as specific antibodies, block alpha-syn transfer, seeding and aggregation?

Our consortium is uniquely positioned to take advantage of combined cutting-edge technologies and complementary, multidisciplinary approaches and novel tools and capabilities developed in each of the participating groups, to address these important issues. These include expertise in unique capabilities in protein chemistry, biochemistry and biophysics, cell and molecular biology, generation of patient-derived stem cells, gut bacteria analysis, animal models of PD and imaging techniques including to study cells by live imaging, as well as live imaging inside the brain. 

The fulfillment of this joint program will contribute significantly to advancing our understanding of how alpha-syn protein aggregation and spread drives PD progression. A better understanding of this process will lead to the identification of novel targets and open new paths for the development of novel therapeutic and preventive interventions. Moreover, it is highly likely that various other misfolded proteins associated with other neurodegenerative diseases may spread through similar mechanisms. Therefore, we anticipate that our findings may also be generally applicable to other neurodegenerative diseases.</gtr:abstractText><gtr:technicalSummary>In the present proposal, we have assembled leading alpha-syn, PD and microbiology research groups in Europe to address major questions. We hypothesize that specific forms of aggregated alpha-syn are key substrates for propagation of synucleinopathy in a first step from the peripheral nervous system to the brain, and then through the different brain regions. In the physiological situation, alpha-syn exists predominantly as a monomer and is enriched in synapses. In pathological states, alpha-syn undergoes structural changes that lead to the formation of oligomers and amyloid fibrils, ultimately leading to the formation of the Lewy Bodies found in PD brains. Accordingly, the initiation and severity of alpha-syn aggregation is highly associated with the levels of alpha-syn (such as in gene multiplications), with mutations, and with different environmental risk factors having a direct or indirect impact on alpha-syn aggregation (such as pesticide exposure or tabacco/caffeine). We will investigate the hypothesis that cell-to-cell propagation of alpha-syn aggregates coupled to the seeding capacity of the aggregates and enironmental impacts play central roles in the spreading of PD pathology and disease progression. The central role of propagation is highlighted by the growing realization that PD may start in the gut and thence spread to the brain via the vagus nerve, though the underlying mechanism remains unresolved. Various post-translational modifications of alpha-syn (such as phosphorylation, truncation, ubiquitination and nitration) not only determine the protein's function, but, more importantly, affect alpha-syn localization, aggregation and spreading between cells. In this complex context, a better understanding of the links between genetic, sequence, biochemical and cellular determinants of alpha-syn oligomerization and amyloid fibril formation, and spreading of the pathology, is essential for the development of novel diagnostic and therapeutic strategies for PD.</gtr:technicalSummary><gtr:potentialImpactText>The aSynProtec consortium will take special measures on exploitation of results and the protection of intellectual property (IP). In brief, if inventions and/or newly generated know-how are considered to be exploitable, each partner will work in close relationship with their tech transfer offices to assist in the exploitation process. 

Three primary areas for exploitation will be considered: 

i) Transfer of know-how: Knowledge transfer will be organized at different levels. 1. Each partner has dedicated a significant proportion of the time of staff scientists to the realization of the goals of this joint program. We will implement this through the training workshops and consortium annual and web meetings. 2. Students or postdoc fellows themselves will be important contributors for transfer between the different centres, and network meetings. Transfer of know how will typically involve obtaining sponsored research from our industrial partner, Lundbeck, to further develop a concept. 

ii) Transfer of IP: The presence of 7 academic partners specializing in both fundamental research, pathophysiological validation and clinical translation, is matched by the involvement of the partner from the private sector, which are well placed to develop commercially important inventions. Our intellectual property strategy is planned to:1. Increase the possibility of licensing, through fully integrated industrial interest and insight; 2. Decrease the costs of failure while increasing the potential revenue. 3. Generate an augmented cost:benefit ratio.

iii) Commercial exploitation: Through our industrial partner of the project, potential customers will be contacted to explore the possibility of exploiting the work performed in aSynProtec.</gtr:potentialImpactText><gtr:fund><gtr:end>2019-07-03</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2016-07-04</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>337257</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>H. Lundbeck A/S</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>JPND Partnership</gtr:description><gtr:id>7CF3DE43-0077-4E9B-903C-ED3D5972D5EB</gtr:id><gtr:impact>Work is ongoing, no outcomes yet.</gtr:impact><gtr:outcomeId>58c9347b7f33b6.88803478-6</gtr:outcomeId><gtr:partnerContribution>Partners provide expertise in post-translational modifications of a-syn and expertise in potential mechanisms of pathological protein spread.</gtr:partnerContribution><gtr:piContribution>We are contributing Parkinson's stem cell derived dopamine neurons to understand the pathological mechanisms of alpha synuclein.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Swiss Federal Institute of Technology in Lausanne (EPFL)</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:description>HL at EPFL</gtr:description><gtr:id>0A20C77B-FEB2-46B6-972B-9734C16DF881</gtr:id><gtr:impact>A visit to EPFL by RWM and SV</gtr:impact><gtr:outcomeId>58c93533cf2fc2.46159984-1</gtr:outcomeId><gtr:partnerContribution>Methods for mass-spec analysis of stem cell-derived neuronal a-syn</gtr:partnerContribution><gtr:piContribution>Methodologies for preparation of intracellular and extracellular a-syn to investigate post-translational modifications</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Lund University</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>JPND Partnership</gtr:description><gtr:id>13FBFE10-3A8D-449E-A53E-A8D83519C9FD</gtr:id><gtr:impact>Work is ongoing, no outcomes yet.</gtr:impact><gtr:outcomeId>58c9347b7f33b6.88803478-1</gtr:outcomeId><gtr:partnerContribution>Partners provide expertise in post-translational modifications of a-syn and expertise in potential mechanisms of pathological protein spread.</gtr:partnerContribution><gtr:piContribution>We are contributing Parkinson's stem cell derived dopamine neurons to understand the pathological mechanisms of alpha synuclein.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of G?ttingen</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Medical School</gtr:department><gtr:description>JPND Partnership</gtr:description><gtr:id>FAF66835-3A4F-4DCE-B0B3-6685A10DB2E6</gtr:id><gtr:impact>Work is ongoing, no outcomes yet.</gtr:impact><gtr:outcomeId>58c9347b7f33b6.88803478-3</gtr:outcomeId><gtr:partnerContribution>Partners provide expertise in post-translational modifications of a-syn and expertise in potential mechanisms of pathological protein spread.</gtr:partnerContribution><gtr:piContribution>We are contributing Parkinson's stem cell derived dopamine neurons to understand the pathological mechanisms of alpha synuclein.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Leuven</gtr:collaboratingOrganisation><gtr:country>Belgium, Kingdom of</gtr:country><gtr:description>JPND Partnership</gtr:description><gtr:id>2C84A3AC-2A9D-4B18-A49D-0E58A432DC0D</gtr:id><gtr:impact>Work is ongoing, no outcomes yet.</gtr:impact><gtr:outcomeId>58c9347b7f33b6.88803478-5</gtr:outcomeId><gtr:partnerContribution>Partners provide expertise in post-translational modifications of a-syn and expertise in potential mechanisms of pathological protein spread.</gtr:partnerContribution><gtr:piContribution>We are contributing Parkinson's stem cell derived dopamine neurons to understand the pathological mechanisms of alpha synuclein.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Swiss Federal Institute of Technology in Lausanne (EPFL)</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:description>JPND Partnership</gtr:description><gtr:id>B8AFF97C-DAF8-4851-9093-5015F2E5ECD4</gtr:id><gtr:impact>Work is ongoing, no outcomes yet.</gtr:impact><gtr:outcomeId>58c9347b7f33b6.88803478-4</gtr:outcomeId><gtr:partnerContribution>Partners provide expertise in post-translational modifications of a-syn and expertise in potential mechanisms of pathological protein spread.</gtr:partnerContribution><gtr:piContribution>We are contributing Parkinson's stem cell derived dopamine neurons to understand the pathological mechanisms of alpha synuclein.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Talk at Parkinson's UK Branch Richard Wade-Martins</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>EFB4241A-471B-45A7-AD95-3BDA4D3D21C8</gtr:id><gtr:impact>Prof Richard Wade-Martins on the latest projects at the Oxford Centre for Parkinson's Disease Research</gtr:impact><gtr:outcomeId>587515c05182d4.99221332</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Oxford Parkinson's Walk 2016</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>F566B62C-3405-4F1D-8269-B2CF364D0177</gtr:id><gtr:impact>Steph Cragg Spoke at the start of the walk about our research
Mel Witt had an information stand with OPDC literature available
Richard Wade-Martins, Siv Vignill, Natalie Connor-Robson and YF Zhang took part in walk and chatted about our work with participants.</gtr:impact><gtr:outcomeId>5874da779e8734.74814327</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Supporters</gtr:primaryAudience><gtr:url>http://www.parkinsons.org.uk/content/walk-parkinsons-oxford</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Parkinson's UK Christmas Concert</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>556FE6B6-3D2B-42A1-AB1C-D9B4708EFCFF</gtr:id><gtr:impact>Michele Hu spoke at the event about our research and OPDC featured in the programme</gtr:impact><gtr:outcomeId>5874ecb5c61cb8.67280789</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Supporters</gtr:primaryAudience><gtr:url>http://www.oxfordmail.co.uk/news/14946354.Star_studded_performance_put_on_at_Christ_Church/</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Methods by ELISA or protein gel electrophoresis to quantify and characterise release of extra-cellular a-syn in neuronal medium</gtr:description><gtr:id>69C212C5-5FDB-4C06-AB7A-0D600790BDC2</gtr:id><gtr:impact>We have been able to define the high molecular weight nature of a-syn released from Parkinson's patient stem cell-derived neurons</gtr:impact><gtr:outcomeId>58c957c7cb9fa2.60183762</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Extracellular a-syn assays</gtr:title><gtr:type>Model of mechanisms or symptoms - in vitro</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>A method to assay uptake of fluorescently-labelled a-syn fibrils into human stem cell-derived dopamine neurons</gtr:description><gtr:id>1F8FDD9F-43EA-4A75-9D83-7E0396148DE6</gtr:id><gtr:impact>We will be able to assess if neurons from patients differ from controls in their ability to take up a-syn fibrils</gtr:impact><gtr:outcomeId>58c9571f916df2.31336241</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>a-syn uptake assays</gtr:title><gtr:type>Model of mechanisms or symptoms - in vitro</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Generation and analysis of induced pluripotent stem cell models of neurodegenerative disease</gtr:description><gtr:id>537B541D-25CA-43B8-A0EF-81BA4948AA9C</gtr:id><gtr:impact>Improved understanding of the mechanisms of neurodegenerative disease</gtr:impact><gtr:outcomeId>e3USjJKgu93</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Stem cell models</gtr:title><gtr:type>Cell line</gtr:type><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have optimised a live cell imaging protocol for the visualisation and measurement of mitochondrial membrane potential in differentiated neurons.</gtr:description><gtr:id>23B11964-4AF4-4100-9162-7270D8314510</gtr:id><gtr:impact>The membrane potential-sensing dye TMRM can be used to quantify membrane potential, with increased fluorescence indicating increased membrane potential.</gtr:impact><gtr:outcomeId>54b6841230ab09.24845663</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Live cell imaging techniques in iPS-derived DA neurons in vitro</gtr:title><gtr:type>Cell line</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>9DCE0403-55E9-42F3-A758-5DA06A808C0E</gtr:id><gtr:title>Are rodent models of Parkinson's disease behaving as they should?</gtr:title><gtr:parentPublicationTitle>Behavioural brain research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/887bad7378d8b8841027d473a9fb0464"><gtr:id>887bad7378d8b8841027d473a9fb0464</gtr:id><gtr:otherNames>Vingill S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0166-4328</gtr:issn><gtr:outcomeId>5a538286262956.48131974</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/N029453/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>